Melatonin in ovarian function and dysfunction: Molecular mechanisms and therapeutic potential.

Authors

Xuanrui Zhao, Yan Zhang, Kaixin Ding, Ziying Qiu, Yinan Wang, Xiaowei Yu

Published in

Journal of ovarian research. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

Melatonin (MT) is a natural indoleamine compound. In addition to regulating sleep and circadian rhythms, MT exhibits antioxidative, anti-inflammatory, anti-apoptotic, and ovarian protective properties. Recent studies have shown that MT alleviates polycystic ovary syndrome (PCOS), premature ovarian insufficiency (POI), ovarian injury, and age-related ovarian function decline. This review establishes an integrated mechanistic model in which oxidative stress, mitochondrial dysfunction, inflammatory responses, and autophagic imbalance collectively contribute to the pathogenesis of ovarian disorders, while melatonin acts as a pleiotropic regulator that counteracts these interconnected pathological pathways. Furthermore, this review also discusses recent advances regarding the inhibitory effects of melatonin on ovarian tumors. Although MT shows considerable clinical promise, further research is needed to determine its optimal dosage, administration regimens, and therapeutic targets to facilitate its clinical translation.

PMID:
42399726
Bibliographic data and abstract were imported from PubMed on 04 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.